TP53 and breast cancer: This conclusion is based on the following: 1) transfection with an expression vector encoding wt or mutant p53 induced galectin-7 in several breast cancer cell lines, including p53null cells; 2) treatment of breast cancer cells harboring wild-type or mutated allele of TP53 with Dox induced galectin-7 expression in human cancer cell lines, and 3) depletion of endogenous p53 inhibited Dox-induced galectin-7 expression.